Metabolic syndrome: Its history, mechanisms, and limitations

Acta Diabetologica

Volumn 49, Issue 2, 2012, Pages 89-95

  Oda, Eiji ^a  

^a Tachikawa Medical Center   (Japan)

Author keywords

Inflammation; Insulin resistance; Metabolic syndrome; Obesity

Indexed keywords

ADIPONECTIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LEPTIN; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ABDOMINAL OBESITY; BODY MASS; CARDIOMETABOLIC RISK; CARDIOVASCULAR RISK; CELLULAR STRESS SIGNAL; CORONARY ARTERY CALCIFICATION; DIABETIC OBESITY; DISEASE ACTIVITY; GENETIC PREDISPOSITION; GLUCOSE INTOLERANCE; HUMAN; HYPERINSULINEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; METABOLIC SYNDROME X; MOLECULAR INTERACTION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OMENTECTOMY; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; ROUX Y ANASTOMOSIS; SOFT TISSUE INFLAMMATION; STOMACH BYPASS; TRIACYLGLYCEROL BLOOD LEVEL;

ANIMALS; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; METABOLIC SYNDROME X; OBESITY;

EID: 84862850517     PISSN: 09405429     EISSN: 14325233     Source Type: Journal    
DOI: 10.1007/s00592-011-0309-6     Document Type: Review

References (72)

1. Reaven GM (1988) Role of insulin resistance in human disease. Diabetes 37:1595-1607
2. World Health Organization (1999) Definition, diagnosis, and classification of diabetes mellitus and its complications: report of a WHO Consultation. World Health Org, Geneva
3. Expert panel on the detection, evaluation, and treatment of high blood cholesterol in adults (2001) Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult treatment panel III). JAMA 285: 2486-2497
4. Alberti KGMM, Zimmet P, Shaw J (2006) Metabolic syndromēa new world-wide definition. A consensus statement from the international diabetes federation. Diabet Med 23:469-480
5. Grundy SM, Cleeman JI, Daniels SR et al (2005) Diagnosis and management of the metabolic syndrome: a statement for health care professionals: an American heart association/National heart, lung, and blood institute scientific statement. Circulation 112:2735-2752 (Pubitemid 41532612)
6. Alberti KGMM, Eckel RH, Grundy SM et al (2009) Harmonizing the metabolic syndrome. A joint interim statement of the international diabetes federation task force on epidemiology and prevention; National heart, lung, and blood institute; American heart association; World heart federation; International atherosclerosis society; and International association for the study of obesity. Circulation 120:1640-1645
7. Matsuzawa YM (1997) Pathophysiology and molecular mechanism of visceral fat syndrome: the Japanese experience. Diabetes Metab Rev 13:3-13
8. The Examination Committee for Criteria of Metabolic Syndrome (2005) Definition and criteria of metabolic syndrome. J Jpn Soc Intern Med 94:794-809 (in Japanese)
9. Kahn R, Buse J, Ferrannini E, Stern M (2005) The metabolic syndrome: time for a critical appraisal: joint statement from the American diabetes association and the European association for the study of diabetes. Diabetes Care 28:2289-2304 (Pubitemid 41242486)
10. Simmons RK, Alberti KG, Gale EA et al (2010) The metabolic syndrome: useful concept or clinical tool? Report of a WHO Expert Consultation. Diabetologia 53:600-605
11. Oda E (2008) The metabolic syndrome as a concept of adipose tissue disease. Hypertens Res 31:1283-1291
12. Cinti S, Mitchell G, Barbatelli G et al (2005) Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans. J Lipid Res 46:2347-2355 (Pubitemid 41532523)
13. Vague J (1956) The degree of masculine differentiation of obesities: a factor determining predisposition to diabetes, atherosclerosis, gout, uric calculous disease. Am J Clin Nutr 4:20-34
14. Ruderman NB, Schneider SH, Berchtold P (1981) The "metabolically- obese", normal-weight individual. Am J Clin Nutr 34:1617-1621
15. Kissebah AH, Vydelingum N, Murray R et al (1982) Relation of body fat distribution to metabolic complications of obesity. J Clin Endocrinol Metab 54:254-260 (Pubitemid 12006594)
16. Fujioka S, Matsuzawa Y, Tokunaga K, Tarui S (1987) Contribution of intra-abdominal fat accumulation to the impairment of glucose and lipid metabolism in human obesity. Metabolism 36:54-59 (Pubitemid 17016386)
17. Ferrannini E, Buzzigoli G, Bonadonna R et al (1987) Insulin resistance in essential hypertension. N Engl J Med 317:350-357 (Pubitemid 17118813)
18. Kaplan (1989) The deadly quartet. Upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension. Arch Intern Med 149:1514-1520
19. DeFronzo RA, Ferrannini E (1991) Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 14:173-194
20. Lemieux I, Pascot A, Couillard C et al (2000) Hypertriglyceridemic waist. A marker of the atherogenic metabolic triad (hyperinsulinemia; hyperapolipoprotein B; small, dense LDL) in men? Circulation 102:179-184 (Pubitemid 30451774)
21. Balkau B, Charles MA (1999) Comment on the provisional report from the WHO consultation. European group for the study of insulin resistance (EGIR). Diabet Med 16:442-443
22. Einhorn D, Reaven GM, Cobin RH et al (2003) American College of Endocrinology position statement on the insulin resistance syndrome. Endocr Pract 9:237-252
23. Ridker PM, Wilson PWF, Grandy SM (2004) Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk? Circulation 109:2818-2825 (Pubitemid 38780294)
24. Reaven GM (2006) The metabolic syndrome: is this diagnosis necessary? Am J Clin Nutr 83:1237-1247
25. Klein S, Allison DB, Heymsfield SB et al (2007) Waist circumference and cardiometabolic risk: a consensus statement from Shaping America's Health: Association for Weight Management and Obesity Prevention; NAASO, The Obesity Society; the American Society for Nutrition; and the American Diabetes Association. Diabetes Care 30:1647-1652 (Pubitemid 46871194)
26. Fox CS, Massaro JM, Hoffmann U et al (2007) Abdominal visceral and subcutaneous adipose tissue compartments. Association with metabolic risk factors in the Framingham Heart Study. Circulation 116:39-48 (Pubitemid 47016245)
27. Pou KM, Massaro JM, Hoffmann U et al (2007) Visceral and subcutaneous adipose tissue volumes are cross-sectionally related to markers of inflammation and oxidative stress. The Framingham Heart Study. Circulation 116:1234-1241 (Pubitemid 47517534)
28. Fox CS, Hwang S-J, Massaro JM et al (2009) Relation of subcutaneous and visceral adipose tissue to coronary and abdominal aortic calcium (from the Framingham Heart Study). Am J Cardiol 104:543-547
29. Herrera MF, Pantoja JP, Velázquez-Fernández D et al (2010) Potential additional effect of omentectomy on metabolic syndrome, acute-phase reactants, and inflammatory mediators in Grade III obese patients undergoing Laparoscopic Roux-en-Y gastric bypass. A randomized trial. Diabetes Care 33:1413-1418
30. Oda E, Kawai R (2011) Changes in body weight are significantly associated with changes in fasting plasma glucose and HDL cholesterol in Japanese men without abdominal obesity (waist circumference <85 cm). Acta Diabetol 48:143-148
31. Kadota A, Hozawa A, Okamura T et al (2007) Relationship between metabolic risk factor clustering and cardiovascular mortality stratified by high blood glucose and obesity: NIPPON DATA90, 1990-2000. Diabetes Care 30:1533-1538 (Pubitemid 46871166)
32. Saito I, Iso H, Kokubo Y, Inoue M, Tsugane S (2009) Metabolic syndrome and all-cause and cardiovascular disease mortality: Japan Public Health Center-based Prospective (JPHC) Study. Circ J 73:878-884
33. Noda H, Iso H, Saito I et al (2009) The impact of the metabolic syndrome and its components on the incidence of ischemic heart disease and stroke: Japan public health center-based study. Hypertens Res 32:289-298
34. Hotamisligil GS, Shargill NS, Spiegelman BM (1993) Adipose expression of tumor necrosis factor-a: direct role in obesity-linked insulin resistance. Science 259:87-91 (Pubitemid 23036092)
35. Velloso LA, Folli F, Sun XJ, White MF, Saad MJ, Kahn CR (1996) Cross-talk between the insulin and angiotensin signaling systems. Proc Natl Acad Sci USA 93:12490-12495 (Pubitemid 26367171)
36. Folli F, Kahn CR, Hansen H, Bouchie JL, Feener EP (1997) Angiotensin II inhibits insulin signaling in aortic smooth muscle cells at multiple levels. A potential role for serine phosphorylation in insulin/angiotensin II crosstalk. J Clin Invest 100: 2158-2169 (Pubitemid 27500137)
37. Federici M, Hribal ML, Menghini R et al (2005) Timp3 deficiency in insulin receptor-haploinsufficient mice promotes diabetes and vascular inflammation via increased TNF-alpha. J Clin Invest 115:3494-3505 (Pubitemid 43121837)
38. Monroy A, Kamath S, Chavez AO et al (2009) Impaired regulation of the TNF-alpha converting enzyme/tissue inhibitor of metalloproteinase 3 proteolytic system in skeletal muscle of obese type 2 diabetic patients: a new mechanism of insulin resistance in humans. Diabetologia 52:2169-2181
39. Devaraj S, Swarbrick MM, Singh U, Adams-Huet B, Havel PJ, Jialal I (2008) CRP and adiponectin and its oligomers in the metabolic syndrome: evaluation of new laboratory-based biomarkers. Am J Clin Pathol 129:815-822
40. Semenkovich CF (2006) Insulin resistance and atherosclerosis. J Clin Invest 116:1813-1822
41. Kolak M, Westerbacka J, Velagapudi VR et al (2007) Adipose tissue inflammation and increased ceramide content characterized subjects with high liver fat content independent of obesity. Diabetes 56:1960-1968 (Pubitemid 47195815)
42. Katagiri H, Yamada T, Oka Y (2007) Adiposity and cardiovascular disorders: disturbance of the regulatory system consisting of humoral and neuronal signals. Circ Res 101:27-39 (Pubitemid 47094621)
43. Dandona P, Aljada A, Chaudhuri A, Mohanty P, Garg R (2005) Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and inflammation. Circulation 111:1448-1454 (Pubitemid 40396812)
44. Kim J, Montagnani M, Koh KK, Quon MJ (2006) Reciprocal relationships between insulin resistance and endothelial dysfunction. Molecular and pathophysiological mechanisms. Circulation 113:1888-1904 (Pubitemid 43739401)
45. Bains RK, Wells SE, Flavell DM et al (2004) Visceral obesity without insulin resistance in late-onset obesity rats. Endocrinology 145:2666-2679 (Pubitemid 38686213)
46. Kanda H, Tateya S, Tamori Y et al (2006) MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J Clin Invest 116:1494-1505
47. Kamei N, Tobe K, Suzuki R et al (2006) Overexpression of monocyte chemoattractant protein-1 in adipose tissue causes macrophage recruitment and insulin resistance. J Biol Chem 281: 26602-26614 (Pubitemid 44401869)
48. Kim JY, Wall E, Laplante M et al (2007) Obesity-associated improvements in metabolic profile through expansion of adipose tissue. J Clin Invest 117:2621-2637 (Pubitemid 47494363)
49. Strissel KJ, Stancheva Z, Miyoshi H et al (2007) Adipocyte death, adipose tissue remodeling, and obesity complications. Diabetes 56:2910-2918 (Pubitemid 350223625)
50. Oda E, Kawai R (2010) Comparison among body mass index (BMI), waist circumference (WC), and percent body fat (%BF) as anthropometric markers for the clustering of metabolic risk factors in Japanese. Intern Med 49:1477-1482
51. Oda E, Kawai R (2010) Body mass index is more strongly associated with hypertension than waist circumference in apparently healthy Japanese men and women. Acta Diabetol 47:309-313
52. The emerging risk factors collaboration (2011) Separate and combined associations of body-mass index and abdominal adiposity with cardiovascular disease: collaborative analysis of 58 prospective studies. Lancet 377:1085-1095
53. Salminen M, Kuoppamäki M, Vahlberg T, Räihä I, Irjala K, Kivelä SL (2011) Metabolic syndrome and vascular risk: a 9-year follow-up among the aged in Finland. Acta Diabetol 48:157-165
54. Ertek S, Cicero AF, Cesur M et al (2011) The severity of coronary atherosclerosis in diabetic and nondiabetic metabolic syndrome patients diagnosed according to different criteria and undergoing elective angiography. Acta Diabetol 48:21-27
55. Fadini GP, de Kreutzenberg SV, Gjini R, Avogaro A (2011) The metabolic syndrome influences the response to incretin-based therapies. Acta Diabetol. May 15. [Epub ahead of print] PubMed PMID: 21574000
56. Ruan W, Lai M (2010) Insulin-like growth factor binding protein: a possible marker for the metabolic syndrome? Acta Diabetol 47:5-14
57. Oda E, Kawai R (2009) Comparison between high-sensitivity C-reactive protein (hs-CRP) and white blood cell count (WBC) as an inflammatory component of metabolic syndrome in Japanese. Intern Med 49:117-124
58. Kotronen A, Yki-Järvinen H (2008) Fatty liver: a novel component of the metabolic syndrome. Arterioscler Thromb Vasc Biol 28:27-38
59. Hanley AJG, Williams K, Festa A, Wagenknecht LE, D'Agostino RB Jr, Haffner SM (2005) Liver markers and development of the metabolic syndrome. The insulin resistance atherosclerosis study. Diabetes 54:3140-3147 (Pubitemid 43334367)
60. Lee DS, Evans JC, Robins SJ et al (2007) Gamma glutamyl transferase and metabolic syndrome, cardiovascular disease, and mortality risk: the Framingham heart study. Arterioscler Thromb Vasc Biol 27:127-133 (Pubitemid 46360389)
61. Halimi JM, Bonnet F, Lange C et al (2008) Urinary albumin excretion is a risk factor for diabetes mellitus in men, independently of initial metabolic profile and development of insulin resistance. The DESIR Study. J Hypertens 26:2096-2100
62. Brantsma AH, Bakker SJL, Hillege HL et al (2005) Urinary albumin excretion and its relation with C-reactive protein and the metabolic syndrome in the prediction of type 2 diabetes. Diabetes Care 28:2525-2530 (Pubitemid 41384305)
63. Monami M, Pala L, Bardini G et al (2009) Glomerular hyperfiltration and metabolic syndrome: results from the FIrenze-BAgno A Ripoli (FIBAR) Study. Acta Diabetol 46:191-196
64. Luk AO, So WY, Ma RC et al (2008) Metabolic syndrome predicts new onset of chronic kidney disease in 5829 patients with type 2 diabetes: a 5-year prospective analysis of the Hong Kong Diabetes Registry. Diabetes Care 31:2357-2361
65. Kurella M, Lo JC, Chertow GM (2005) Metabolic syndrome and the risk for chronic kidney disease among nondiabetic adults. J Am Soc Nephrol 16:2134-2140 (Pubitemid 41716445)
66. Lucove J, Yupputuri S, Heiss G et al (2008) Metabolic syndrome and the development of CKD in American Indians: the strong heart study. Am J Kidney Dis 51:21-28 (Pubitemid 350296515)
67. Esteghamati A, Rashidi A, Khalilzadeh O, Ashraf H, Abbasi M (2010) Metabolic syndrome is independently associated with microalbuminuria in type 2 diabetes. Acta Diabetol 47:125-130
68. Yeh H, Punjabi NM, Wang N, Pankow JS, Duncan BB, Brancati FL (2005) Vital capacity as a predictor of incident type 2 diabetes. The atherosclerosis risk in communities study. Diabetes Care 28:1472-1479 (Pubitemid 40756715)
69. Oda E, Kawai R (2009) A cross-sectional relationship between vital capacity and diabetes in Japanese men. Diabetes Res Clin Pract 85:111-116
70. Oda E, Kawai R (2009) Significance of heart rate on the prevalence of metabolic syndrome and its related risk factors in Japanese. Circ J 73:1431-1436
71. Fox K, Borer JS, Camm AJ et al (2007) Resting heart rate in cardiovascular disease. J Am Coll Cardiol 50:823-830 (Pubitemid 47277500)
72. Nicolucci A (2010) Epidemiological aspects of neoplasms in diabetes. Acta Diabetol 47:87-95